Clearside Biomedical Management
Management criteria checks 2/4
Clearside Biomedical's CEO is George Lasezkay, appointed in Apr 2019, has a tenure of 5.67 years. total yearly compensation is $1.54M, comprised of 35.6% salary and 64.4% bonuses, including company stock and options. directly owns 0.5% of the company’s shares, worth $333.89K. The average tenure of the management team and the board of directors is 2.4 years and 5.5 years respectively.
Key information
George Lasezkay
Chief executive officer
US$1.5m
Total compensation
CEO salary percentage | 35.6% |
CEO tenure | 5.7yrs |
CEO ownership | 0.5% |
Management average tenure | 2.4yrs |
Board average tenure | 5.5yrs |
Recent management updates
Recent updates
Here's Why We're Watching Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation
Nov 06We're Keeping An Eye On Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Rate
Jun 24Here's Why We're Not At All Concerned With Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation
Nov 12Analyst Forecasts Just Became More Bearish On Clearside Biomedical, Inc. (NASDAQ:CLSD)
Aug 11Clearside Biomedical Q2 2022 Earnings Preview
Aug 08Clearside Biomedical: A Pivotal 2022 Ahead
Apr 13Clearside's Safety Data In Wet AMD And Emphasis On SCS Microinjector Make It Great Speculative Play
Dec 22Clearside Biomedical (NASDAQ:CLSD) Is In A Strong Position To Grow Its Business
Sep 30Clearside's Value Proposition Is Far From Clear
Aug 07We Think Clearside Biomedical (NASDAQ:CLSD) Can Easily Afford To Drive Business Growth
Jun 17Clearside Biomedical climbs after positive results from early-stage wet AMD trial
Jun 15Clearside Biomedical resubmits eye treatment XIPERE NDA
May 03If You Had Bought Clearside Biomedical (NASDAQ:CLSD) Shares A Year Ago You'd Have Earned 45% Returns
Feb 16CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Sep 30 2024 | n/a | n/a | -US$32m |
Jun 30 2024 | n/a | n/a | -US$33m |
Mar 31 2024 | n/a | n/a | -US$35m |
Dec 31 2023 | US$2m | US$547k | -US$32m |
Sep 30 2023 | n/a | n/a | -US$37m |
Jun 30 2023 | n/a | n/a | -US$36m |
Mar 31 2023 | n/a | n/a | -US$35m |
Dec 31 2022 | US$2m | US$532k | -US$33m |
Sep 30 2022 | n/a | n/a | -US$5m |
Jun 30 2022 | n/a | n/a | -US$2m |
Mar 31 2022 | n/a | n/a | US$83k |
Dec 31 2021 | US$2m | US$516k | US$376k |
Sep 30 2021 | n/a | n/a | -US$25m |
Jun 30 2021 | n/a | n/a | -US$23m |
Mar 31 2021 | n/a | n/a | -US$23m |
Dec 31 2020 | US$1m | US$503k | -US$18m |
Sep 30 2020 | n/a | n/a | -US$14m |
Jun 30 2020 | n/a | n/a | -US$18m |
Mar 31 2020 | n/a | n/a | -US$18m |
Dec 31 2019 | US$1m | US$385k | -US$31m |
Sep 30 2019 | n/a | n/a | -US$49m |
Jun 30 2019 | n/a | n/a | -US$67m |
Mar 31 2019 | n/a | n/a | -US$82m |
Dec 31 2018 | US$150k | n/a | -US$83m |
Sep 30 2018 | n/a | n/a | -US$78m |
Jun 30 2018 | n/a | n/a | -US$72m |
Mar 31 2018 | n/a | n/a | -US$65m |
Dec 31 2017 | US$167k | n/a | -US$59m |
Compensation vs Market: George's total compensation ($USD1.54M) is above average for companies of similar size in the US market ($USD653.16K).
Compensation vs Earnings: George's compensation has increased whilst the company is unprofitable.
CEO
George Lasezkay (72 yo)
5.7yrs
Tenure
US$1,538,627
Compensation
Dr. George M. Lasezkay, Pharm D, & J.D. has been Chief Executive Officer at Clearside BioMedical, Inc. since March 2020, serves as President since March 1, 2020 and served as its Interim Chief Executive Of...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
President | 5.7yrs | US$1.54m | 0.50% $ 333.9k | |
Chief Financial Officer | 12.9yrs | US$854.41k | 0.44% $ 294.4k | |
Head of Investor Relations | no data | no data | no data | |
Senior Vice President of Corporate Development & Alliance Management | 2.3yrs | no data | no data | |
Senior Vice President of Engineering & Manufacturing | 1.9yrs | no data | no data | |
Chief Clinical Officer | 2.5yrs | no data | no data | |
Chief Medical Officer | less than a year | no data | 0.13% $ 87.2k | |
Secretary | no data | no data | no data |
2.4yrs
Average Tenure
59yo
Average Age
Experienced Management: CLSD's management team is considered experienced (2.4 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
President | 7.3yrs | US$1.54m | 0.50% $ 333.9k | |
Independent Director | 12.9yrs | US$86.08k | 0.0058% $ 3.8k | |
Independent Director | 2.8yrs | US$88.58k | 0.024% $ 15.7k | |
Independent Director | 6.3yrs | US$88.58k | 0% $ 0 | |
Independent Director | 12.9yrs | US$96.08k | 0.053% $ 35.3k | |
Member of Scientific Advisory Board | 4.7yrs | no data | no data | |
Independent Director | 12.9yrs | US$91.71k | 0.067% $ 44.5k | |
Member of Scientific Advisory Board | 4.7yrs | no data | no data | |
Independent Director | 4.7yrs | US$85.46k | 0.12% $ 81.1k | |
Independent Director | 8.8yrs | US$91.08k | 0% $ 0 | |
Chairman of the Board | less than a year | no data | 0.13% $ 87.2k | |
Member of Scientific Advisory Board | 1.7yrs | no data | no data |
5.5yrs
Average Tenure
63yo
Average Age
Experienced Board: CLSD's board of directors are considered experienced (5.5 years average tenure).
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/23 13:28 |
End of Day Share Price | 2024/12/20 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Clearside Biomedical, Inc. is covered by 13 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Daniil Gataulin | Chardan Capital Markets, LLC |
Yi Chen | H.C. Wainwright & Co. |
Esther Lannie Hong | Janney Montgomery Scott LLC |